FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2770348953> ?p ?o ?g. }

• W2770348953 endingPage "340" @default.
• W2770348953 startingPage "331" @default.
• W2770348953 abstract "Rationale: Isoniazid-monoresistant tuberculosis (INH-monoresistant TB) is the most common drug-resistant TB type in the United States; however, its impact on TB treatment outcomes is not clear.Objectives: This study aims to understand 1) factors associated with INH-monoresistant TB and 2) the association between INH monoresistance and response to TB treatment.Methods: We studied all patients with TB (age, ≥15 yr) reported to the Georgia State Electronic Notifiable Disease Surveillance System (SENDSS) from 2009 to 2014. INH-monoresistant TB was defined as a Mycobacterium tuberculosis isolate resistant to isoniazid only. Time to sputum culture conversion was defined as the time (measured in days) from TB treatment initiation to the date of the first consistently negative culture result reported to the SENDSS. Logistic regression and Cox proportional hazard models were used to estimate the odds and hazard rate of sputum culture conversion, all-cause mortality, and poor TB outcome among patients with INH-monoresistant TB.Results: Among 1,141 culture-confirmed patients with available drug susceptibility testing results, 998 (87.5%) were susceptible to TB first-line drugs, and 143 (12.5%) were patients with INH-monoresistant TB. In multivariable analysis, male sex (adjusted odds ratio [aOR], 1.62; 95% confidence interval [CI], 1.01–2.67) and homelessness (aOR, 5.55; 95% CI, 3.38–9.17) were associated with higher odds of INH-monoresistant TB. In the same multivariable model, older age (≥65 yr old) (aOR, 0.21; 95% CI, 0.07–0.55) and miliary disease (aOR, 0.19; 95% CI, 0.01–0.96) were associated with lower odds of INH-monoresistant TB. Among 1,116 patients with pulmonary TB, the median time to sputum culture conversion was 30 days (interquartile range, 13–58). The rate of culture conversion was similar among patients with and without INH monoresistance (adjusted cause-specific hazard ratio, 1.15; 95% CI, 0.95–1.40). INH-monoresistant TB was not significantly associated with poor TB treatment outcomes (aOR, 1.61; 95% CI, 0.67–3.70) or mortality during TB treatment (aOR, 1.72; 95% CI, 0.58–4.94).Conclusions: Our findings suggest that compared with drug-susceptible TB, patients in Georgia with INH-monoresistant TB have a similar response to TB treatment including culture conversion rate, final TB treatment outcome, and all-cause mortality." @default.
• W2770348953 created "2017-12-04" @default.
• W2770348953 creator A5009197958 @default.
• W2770348953 creator A5018688973 @default.
• W2770348953 creator A5040114846 @default.
• W2770348953 creator A5060011661 @default.
• W2770348953 creator A5066620186 @default.
• W2770348953 creator A5075855225 @default.
• W2770348953 date "2018-03-01" @default.
• W2770348953 modified "2023-09-27" @default.
• W2770348953 title "Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009–2014" @default.
• W2770348953 cites W1777095277 @default.
• W2770348953 cites W1965511350 @default.
• W2770348953 cites W1979316277 @default.
• W2770348953 cites W1980729813 @default.
• W2770348953 cites W2010155045 @default.
• W2770348953 cites W2018615176 @default.
• W2770348953 cites W2062594082 @default.
• W2770348953 cites W2083487129 @default.
• W2770348953 cites W2090542083 @default.
• W2770348953 cites W2096245909 @default.
• W2770348953 cites W2101094926 @default.
• W2770348953 cites W2108762138 @default.
• W2770348953 cites W2112746019 @default.
• W2770348953 cites W2114698696 @default.
• W2770348953 cites W2124243126 @default.
• W2770348953 cites W2125921446 @default.
• W2770348953 cites W2128936931 @default.
• W2770348953 cites W2134639888 @default.
• W2770348953 cites W2141796585 @default.
• W2770348953 cites W2146740990 @default.
• W2770348953 cites W2151757899 @default.
• W2770348953 cites W2156189389 @default.
• W2770348953 cites W2334265466 @default.
• W2770348953 cites W2418210342 @default.
• W2770348953 cites W2426444771 @default.
• W2770348953 cites W2535225711 @default.
• W2770348953 cites W2552825987 @default.
• W2770348953 cites W2562765686 @default.
• W2770348953 cites W2576073187 @default.
• W2770348953 cites W2577692590 @default.
• W2770348953 cites W2592606438 @default.
• W2770348953 cites W2738707028 @default.
• W2770348953 cites W4244009405 @default.
• W2770348953 cites W4294553991 @default.
• W2770348953 cites W2743439170 @default.
• W2770348953 doi "https://doi.org/10.1513/annalsats.201702-147oc" @default.
• W2770348953 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5880520" @default.
• W2770348953 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29131662" @default.
• W2770348953 hasPublicationYear "2018" @default.
• W2770348953 type Work @default.
• W2770348953 sameAs 2770348953 @default.
• W2770348953 citedByCount "11" @default.
• W2770348953 countsByYear W27703489532018 @default.
• W2770348953 countsByYear W27703489532019 @default.
• W2770348953 countsByYear W27703489532020 @default.
• W2770348953 countsByYear W27703489532021 @default.
• W2770348953 countsByYear W27703489532022 @default.
• W2770348953 countsByYear W27703489532023 @default.
• W2770348953 crossrefType "journal-article" @default.
• W2770348953 hasAuthorship W2770348953A5009197958 @default.
• W2770348953 hasAuthorship W2770348953A5018688973 @default.
• W2770348953 hasAuthorship W2770348953A5040114846 @default.
• W2770348953 hasAuthorship W2770348953A5060011661 @default.
• W2770348953 hasAuthorship W2770348953A5066620186 @default.
• W2770348953 hasAuthorship W2770348953A5075855225 @default.
• W2770348953 hasBestOaLocation W27703489532 @default.
• W2770348953 hasConcept C126322002 @default.
• W2770348953 hasConcept C142724271 @default.
• W2770348953 hasConcept C156957248 @default.
• W2770348953 hasConcept C207103383 @default.
• W2770348953 hasConcept C2776301714 @default.
• W2770348953 hasConcept C2776967927 @default.
• W2770348953 hasConcept C2777768864 @default.
• W2770348953 hasConcept C2777975735 @default.
• W2770348953 hasConcept C2779912665 @default.
• W2770348953 hasConcept C2781069245 @default.
• W2770348953 hasConcept C44249647 @default.
• W2770348953 hasConcept C71924100 @default.
• W2770348953 hasConceptScore W2770348953C126322002 @default.
• W2770348953 hasConceptScore W2770348953C142724271 @default.
• W2770348953 hasConceptScore W2770348953C156957248 @default.
• W2770348953 hasConceptScore W2770348953C207103383 @default.
• W2770348953 hasConceptScore W2770348953C2776301714 @default.
• W2770348953 hasConceptScore W2770348953C2776967927 @default.
• W2770348953 hasConceptScore W2770348953C2777768864 @default.
• W2770348953 hasConceptScore W2770348953C2777975735 @default.
• W2770348953 hasConceptScore W2770348953C2779912665 @default.
• W2770348953 hasConceptScore W2770348953C2781069245 @default.
• W2770348953 hasConceptScore W2770348953C44249647 @default.
• W2770348953 hasConceptScore W2770348953C71924100 @default.
• W2770348953 hasIssue "3" @default.
• W2770348953 hasLocation W27703489531 @default.
• W2770348953 hasLocation W27703489532 @default.
• W2770348953 hasLocation W27703489533 @default.
• W2770348953 hasLocation W27703489534 @default.
• W2770348953 hasOpenAccess W2770348953 @default.
• W2770348953 hasPrimaryLocation W27703489531 @default.

• next